摘要
目的观察肥胖2型糖尿病(T2DM)应用达格列净联合利拉鲁肽治疗的临床疗效。方法58例肥胖2型糖尿病患者,根据随机抽样法分成观察组(28例)和对照组(30例)。观察组使用达格列净联合利拉鲁肽治疗,对照组使用利拉鲁肽治疗。比较两组治疗前后的体质量指数(BMI)、空腹血糖(FPG)、餐后2 h血糖(2 h PG)、胰岛素抵抗指数(HOMA-IR)、胰岛β细胞功能指数(HOMA-β)、总胆固醇(TC)、氧化修饰型低密度脂蛋白(OX-LDL)、甘油三酯(TG)水平,不良反应发生情况。结果治疗后,观察患者的BMI(25.01±0.68)kg/m2、FPG(8.79±0.82)mmol/L、2 h PG(11.25±1.96)mmol/L均显著低于对照组的(27.12±1.26)kg/m2、(10.98±1.46)mmol/L、(13.74±2.98)mmol/L,差异具有统计学意义(P<0.05)。治疗后,观察患者的HOMA-IR(2.31±0.19)、TC(5.43±0.36)mmol/L、OX-LDL(2.45±0.51)μg/L、TG(0.65±0.64)mmol/L均低于对照组的(2.78±0.46)、(6.01±1.23)mmol/L、(3.01±0.98)μg/L、(1.23±1.02)mmol/L,HOMA-β(53.78±8.01)高于对照组的(47.98±7.12),差异具有统计学意义(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论达格列净联合利拉鲁肽治疗肥胖2型糖尿病的临床疗效显著。
Objective To observe the clinical efficacy of Dapagliflozin combined with liraglutide in the treatment of obesity type 2 diabetes mellitus(T2DM).Methods A total of 58 cases of obesity type 2 diabetes mellitus were divided into observation group(28 cases)and control group(30 cases)according to random sampling method.The observation group was treated with dapagliflozin and liraglutide,and the control group was treated with liraglutide alone.The body mass index(BMI),fasting plasma glucose(FPG),2 h postprandial glucose(2 h PG),homeostasis model assessment resistance index(HOMA-IR),homeostasis model assessmentβ-cell function index(HOMA-β),total cholesterol(TC),oxidized low-density lipoprotein(OX-LDL),triglyceride(TG)levels before and after treatment,and the occurrence of adverse reactions were compared between the two groups.Results After treatment,BMI(25.01±0.68)kg/m2,FPG(8.79±0.82)mmol/L,and 2 h PG(11.25±1.96)mmol/L of the observation group were significantly lower than(27.12±1.26)kg/m2,(10.98±1.46)mmol/L,(13.74±2.98)mmol/L of the control group,and the differences were statistically significant(P<0.05).After treatment,HOMA-IR(2.31±0.19),TC(5.43±0.36)mmol/L,OX-LDL(2.45±0.51)μg/L,and TG(0.65±0.64)mmol/L in the observation group were lower than(2.78±0.46),(6.01±1.23)mmol/L,(3.01±0.98)μg/L,(1.23±1.02)mmol/L in the control group,and HOMA-β(53.78±8.01)was higher than(47.98±7.12)in the control group.All the differences were statistically significant(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Combination of dapagliflozin and liraglutide has significant efficacy on the treatment of obesity type 2 diabetes mellitus.
作者
郭剑
GUO Jian(Shenyang Fifth People’s Hospital,Shenyang 110023,China)
出处
《中国实用医药》
2021年第27期122-125,共4页
China Practical Medicine
关键词
肥胖2型糖尿病
达格列净
利拉鲁肽
临床疗效
Obesity type 2 diabetes mellitus
Dapagliflozin
Liraglutide
Clinical efficacy
